NYSE:NVTA - Invitae Stock Price, Price Target & More

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae Co. (NYSE:NVTA) posted its quarterly earnings results on Monday, February, 12th. The medical research company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.17. The medical research company had revenue of $25.40 million for the quarter, compared to analyst estimates of $24.18 million. Invitae had a negative return on equity of 124.43% and a negative net margin of 180.85%. The firm's revenue for the quarter was up 175.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.69) EPS. View Invitae's Earnings History.

Invitae is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Invitae.

4 Wall Street analysts have issued 12 month price targets for Invitae's shares. Their predictions range from $9.00 to $15.00. On average, they expect Invitae's share price to reach $11.00 in the next twelve months. View Analyst Ratings for Invitae.

Some companies that are related to Invitae include Genomic Health (GHDX), RadNet (RDNT), Natera (NTRA), Enzo Biochem (ENZ), CareDx (CDNA), Veracyte (VCYT), Miragen Therapeutics (MGEN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and Cord Blood America (CBAI).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

News articles about NVTA stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Invitae earned a coverage optimism score of 0.09 on Accern's scale. They also gave media coverage about the medical research company an impact score of 47.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Invitae's stock is owned by many different of retail and institutional investors. Top institutional investors include WELLINGTON MANAGEMENT PORTFOLIOS (DUBLIN) PUBLIC LTD COMPANY (5.23%). Company insiders that own Invitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum and Thomas Brida. View Institutional Ownership Trends for Invitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $5.64.

Invitae has a market capitalization of $302.32 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Invitae employs 594 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]